Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

west pharmaceutical services inc. - WST

WST

Close Chg Chg %
330.32 -1.57 -0.48%

Closed Market

328.75

-1.57 (0.48%)

Volume: 465.31K

Last Updated:

Jun 12, 2026, 3:59 PM EDT

Trade Now

Company Overview: west pharmaceutical services inc. - WST

WST Key Data

Open

$333.29

 Day Range

327.43 - 334.14

52 Week Range

206.81 - 336.82

 Market Cap

$23.34B

Shares Outstanding

70.65M

 Public Float

70.20M

Beta

1.18

 Rev. Per Employee

N/A

P/E Ratio

44.16

 EPS

$7.52

Yield

26.34%

 Dividend

$0.22

EX-DIVIDEND DATE

Apr 29, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

678.01K

  

WST Performance

1 Week
 
 4.55%
 
1 Month
 
 8.56%
 
3 Months
 
 39.65%
 
1 Year
 
 48.18%
 
5 Years
 
 -4.78%
 

WST Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About west pharmaceutical services inc. - WST

West Pharmaceutical Services, Inc. engages in the design, manufacture, and sale of containment and delivery systems for injectable drugs and healthcare products. It operates through the Proprietary Products and Contract-Manufactured Products segments. The Proprietary Products segment offers proprietary packaging, containment solutions, drug delivery systems, analytical lab services, and other integrated services and solutions, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

WST At a Glance

West Pharmaceutical Services, Inc.
530 Herman O. West Drive
Exton, Pennsylvania 19341-1147
Phone 1-610-594-2900 Revenue 3.07B
Industry Medical Specialties Net Income 493.70M
Sector Health Technology 2025 Sales Growth 6.292%
Fiscal Year-end 12 / 2026 Employees 10,800
View SEC Filings

WST Valuation

P/E Current 44.16
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 40.516
Price to Sales Ratio 6.506
Price to Book Ratio 6.237
Price to Cash Flow Ratio 26.50
Enterprise Value to EBITDA 24.18
Enterprise Value to Sales 6.354
Total Debt to Enterprise Value 0.017

WST Efficiency

Revenue/Employee 284,694.444
Income Per Employee 45,712.963
Receivables Turnover 5.244
Total Asset Turnover 0.777

WST Liquidity

Current Ratio 3.021
Quick Ratio 2.343
Cash Ratio 1.208

WST Profitability

Gross Margin 35.922
Operating Margin 20.704
Pretax Margin 19.543
Net Margin 16.057
Return on Assets 12.478
Return on Equity 16.855
Return on Total Capital 14.097
Return on Invested Capital 15.316

WST Capital Structure

Total Debt to Total Equity 10.271
Total Debt to Total Capital 9.314
Total Debt to Total Assets 7.639
Long-Term Debt to Equity 9.509
Long-Term Debt to Total Capital 8.623
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for West Pharmaceutical Services Inc. - WST

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.89B 2.95B 2.89B 3.07B
Sales Growth
+1.94% +2.27% -1.98% +6.29%
Cost of Goods Sold (COGS) incl D&A
1.75B 1.82B 1.89B 1.97B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
120.60M 137.30M 155.40M 171.40M
Depreciation
116.90M 133.70M 151.80M 168.60M
Amortization of Intangibles
3.70M 3.60M 3.60M 2.80M
COGS Growth
+5.39% +4.11% +3.97% +4.22%
Gross Income
1.14B 1.13B 1.00B 1.10B
Gross Income Growth
-2.94% -0.54% -11.52% +10.21%
Gross Profit Margin
+39.47% +38.38% +34.65% +35.92%
2022 2023 2024 2025 5-year trend
SG&A Expense
375.40M 421.80M 407.60M 467.90M
Research & Development
58.50M 68.40M 69.10M 74.30M
Other SG&A
316.90M 353.40M 338.50M 393.60M
SGA Growth
-9.48% +12.36% -3.37% +14.79%
Other Operating Expense
- - - -
-
Unusual Expense
36.20M 13.80M 19.00M 42.70M
EBIT after Unusual Expense
727.30M 697.10M 575.60M 593.90M
Non Operating Income/Expense
(39.80M) 9.70M 12.80M 7.40M
Non-Operating Interest Income
5.10M 28.00M 19.60M 17.50M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
7.60M 8.80M 2.90M 400.00K
Interest Expense Growth
-10.59% +15.79% -67.05% -86.21%
Gross Interest Expense
11.30M 8.80M 16.10M 15.00M
Interest Capitalized
- 3.70M 13.20M 14.60M
Pretax Income
679.90M 698.00M 585.50M 600.90M
Pretax Income Growth
-9.21% +2.66% -16.12% +2.63%
Pretax Margin
+23.56% +23.65% +20.24% +19.54%
Income Tax
114.70M 122.30M 107.50M 121.60M
Income Tax - Current - Domestic
84.10M 26.00M 31.90M 52.30M
Income Tax - Current - Foreign
61.40M 58.80M 79.10M 83.00M
Income Tax - Deferred - Domestic
(20.30M) (11.60M) (18.30M) (14.00M)
Income Tax - Deferred - Foreign
(10.50M) 49.10M 14.80M 300.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
585.90M 593.40M 492.70M 493.70M
Minority Interest Expense
- - - -
-
Net Income
585.90M 593.40M 492.70M 493.70M
Net Income Growth
-11.47% +1.28% -16.97% +0.20%
Net Margin Growth
+20.30% +20.11% +17.03% +16.06%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
585.90M 593.40M 492.70M 493.70M
Preferred Dividends
- - - -
-
Net Income Available to Common
585.90M 593.40M 492.70M 493.70M
EPS (Basic)
7.875 7.9865 6.7493 6.8285
EPS (Basic) Growth
-11.47% +1.42% -15.49% +1.17%
Basic Shares Outstanding
74.40M 74.30M 73.00M 72.30M
EPS (Diluted)
7.7296 7.8805 6.6852 6.7909
EPS (Diluted) Growth
-10.88% +1.95% -15.17% +1.58%
Diluted Shares Outstanding
75.80M 75.30M 73.70M 72.70M
EBITDA
884.10M 848.20M 750.00M 808.00M
EBITDA Growth
+0.35% -4.06% -11.58% +7.73%
EBITDA Margin
+30.64% +28.74% +25.93% +26.28%

Snapshot

Average Recommendation BUY Average Target Price 355.615
Number of Ratings 18 Current Quarters Estimate 2.08
FY Report Date 06 / 2026 Current Year's Estimate 8.612
Last Quarter’s Earnings 2.13 Median PE on CY Estimate N/A
Year Ago Earnings 7.29 Next Fiscal Year Estimate 9.579
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 14 14
Mean Estimate 2.08 2.12 8.61 9.58
High Estimates 2.10 2.17 8.82 10.28
Low Estimate 2.05 2.08 8.47 9.07
Coefficient of Variance 0.75 1.32 1.04 2.82

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 13
OVERWEIGHT 2 1 1
HOLD 3 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Overweight Overweight

Insider Actions for West Pharmaceutical Services Inc. - WST

Date Name Shares Transaction Value
Apr 30, 2026 Chad R. Winters VP, Chief Accounting Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 30, 2026 Chad R. Winters VP, Chief Accounting Officer 1,523 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $300.67 per share 457,920.41
Apr 30, 2026 Chad R. Winters VP, Chief Accounting Officer 2,419 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $173.22 per share 419,019.18
Apr 30, 2026 Annette F. Favorite Sr. VP & Chief HR Officer 5,635 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 30, 2026 Annette F. Favorite Sr. VP & Chief HR Officer 16,828 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $305.2 per share 5,135,905.60
Apr 30, 2026 Annette F. Favorite Sr. VP & Chief HR Officer 19,645 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $83.47 per share 1,639,768.15
Apr 2, 2026 Janet Brutschea Haugen Director 260 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Rudy Poussot SVP, Strategy & Corporate Dev 437 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Rudy Poussot SVP, Strategy & Corporate Dev 1,040 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Shane Campbell SVP, Proprietary Segment 2,691 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Eric Mark Green President, CEO and Board Chair; Director 6,986 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Robert W. McMahon SVP & Chief Financial Officer 7,337 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Robert W. McMahon SVP & Chief Financial Officer 3,082 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Norman D. Finch SVP, GC & Corporate Secretary 3,057 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Norman D. Finch SVP, GC & Corporate Secretary 1,285 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Shane Campbell SVP, Proprietary Segment 1,131 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Eric Mark Green President, CEO and Board Chair; Director 16,630 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Charles Witherspoon VP & Treasurer 1,370 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $243.19 per share 333,170.30
Feb 20, 2026 Annette F. Favorite Sr. VP & Chief HR Officer 17,410 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2026 Eric Mark Green President, CEO and Board Chair; Director 175,161 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $248.26 per share 43,485,469.86

West Pharmaceutical Services Inc. in the News